Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system

[1]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[2]  A. Stanton,et al.  Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker , 2007, Hypertension.

[3]  N. Hollenberg.  The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step? , 2007, Reviews in cardiovascular medicine.

[4]  Roland E Schmieder,et al.  Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. , 2007, American journal of hypertension.

[5]  J. Cohn.  Is it the blood pressure or the blood vessel? , 2007, Journal of the American Society of Hypertension : JASH.

[6]  H. Clark,et al.  Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Martin Paul,et al.  Physiology of local renin-angiotensin systems. , 2006, Physiological reviews.

[8]  E. Bonora,et al.  Metabolic syndrome and cardiovascular disease , 2007, Annals of clinical biochemistry.

[9]  A. Voors,et al.  Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? , 2005, European heart journal.

[10]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[11]  H. Investigators,et al.  Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. , 2005 .

[12]  N. Sayar,et al.  Long-term combined therapy with losartan and an angiotensin-converting enzyme inhibitor improves functional capacity in patients with left ventricular dysfunction. , 2005, Acta cardiologica.

[13]  S. Solomon,et al.  Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction , 2005, Circulation.

[14]  H. Diener,et al.  Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES) , 2005, Stroke.

[15]  J. Staessen,et al.  Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003–2004 Secondary Prevention Trials , 2005, Hypertension Research.

[16]  G. MacGregor,et al.  Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension , 2005, Hypertension.

[17]  H. Schunkert,et al.  ACE inhibitors and angiotensin II receptor antagonists. , 2005, Handbook of experimental pharmacology.

[18]  J. Cohn,et al.  Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val‐HeFT , 2004, European journal of heart failure.

[19]  T. Taguchi,et al.  Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[20]  J. Mustonen,et al.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. , 2004, The New England journal of medicine.

[21]  S. Solomon,et al.  Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program , 2004, Circulation.

[22]  S. Erdine,et al.  Current status of hypertension control around the world. , 2004, Clinical and experimental hypertension.

[23]  M. Fukagawa,et al.  Effects of Combination Treatment with Losartan and Trandolapril on Office and Ambulatory Blood Pressures in Non-Diabetic Renal Disease: A COOPERATE-ABP Substudy , 2004, American Journal of Nephrology.

[24]  A. Hofman,et al.  Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). , 2004, Journal of the American College of Cardiology.

[25]  S. Yusuf,et al.  Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Int , 2004, American heart journal.

[26]  K. Fox.  The EUROPA trial , 2003, The Lancet.

[27]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[28]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[29]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[30]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[31]  H. Morita,et al.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.

[32]  H. Parving,et al.  Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. , 2003, Journal of the American Society of Nephrology : JASN.

[33]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[34]  H. Morita,et al.  RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.

[35]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[36]  M. Volpe,et al.  The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[37]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[38]  B. Rutkowski,et al.  Renoprotective Effect of Small Doses of Losartan and Enalapril in Patients with Primary Glomerulonephritis , 2002, American Journal of Nephrology.

[39]  J. Bosch,et al.  Use of ramipril in preventing stroke: double blind randomised trial , 2002, BMJ : British Medical Journal.

[40]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[41]  T. Unger.  The role of the renin-angiotensin system in the development of cardiovascular disease. , 2002, The American journal of cardiology.

[42]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[43]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[44]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[45]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[46]  J. Ménard,et al.  Pilot study of combined blockade of the renin–angiotensin system in essential hypertensive patients , 2000, Journal of hypertension.

[47]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[48]  L. Ruilope,et al.  Safety of the combination of valsartan and benazepril in patients with chronic renal disease , 2000, Journal of hypertension.

[49]  F. Locatelli,et al.  Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial , 1999 .

[50]  J. Ménard,et al.  Additive effects of losartan and enalapril on blood pressure and plasma active renin. , 1997, Hypertension.

[51]  E. Fleck,et al.  Hemodynamic and Neurohormonal Effects of the Angiotensin II Antagonist Losartan in Patients With Congestive Heart Failure , 1993, Circulation.

[52]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[53]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[54]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[55]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.